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Phylogenetic analysis has demonstrated that some positive-sense RNA viruses can be classified into the picornavirus-like super-
cluster, which includes picornaviruses, caliciviruses, and coronaviruses. These viruses possess 3C or 3C-like proteases (3Cpro or
3CLpro, respectively), which contain a typical chymotrypsin-like fold and a catalytic triad (or dyad) with a Cys residue as a nu-
cleophile. The conserved key sites of 3Cpro or 3CLpro may serve as attractive targets for the design of broad-spectrum antivirals
for multiple viruses in the supercluster. We previously reported the structure-based design and synthesis of potent protease in-
hibitors of Norwalk virus (NV), a member of the Caliciviridae family. We report herein the broad-spectrum antiviral activities of
three compounds possessing a common dipeptidyl residue with different warheads, i.e., an aldehyde (GC373), a bisulfite adduct
(GC376), and an -ketoamide (GC375), against viruses that belong to the supercluster. All compounds were highly effective
against the majority of tested viruses, with half-maximal inhibitory concentrations in the high nanomolar or low micromolar
range in enzyme- and/or cell-based assays and with high therapeutic indices. We also report the high-resolution X-ray cocrystal
structures of NV 3CLpro-, poliovirus 3Cpro-, and transmissible gastroenteritis virus 3CLpro- GC376 inhibitor complexes, which
show the compound covalently bound to a nucleophilic Cys residue in the catalytic site of the corresponding protease. We con-
clude that these compounds have the potential to be developed as antiviral therapeutics aimed at a single virus or multiple vi-
ruses in the picornavirus-like supercluster by targeting 3Cpro or 3CLpro.
Positive-sense RNA viruses possess RNA that is translated di-rectly into one or more polyproteins which are subsequently
cleaved by virus proteases into mature or intermediate viral pro-
teins. Genetic analysis of RNA-dependent RNA polymerase has
demonstrated that some positive-sense RNA viruses can be clas-
sified further into the picornavirus-like supercluster, which in-
cludes viruses belonging to the Picornaviridae, Caliciviridae, and
Coronaviridae families (16). Viruses in the picornavirus-like su-
percluster include important classical and emerging human and
animal pathogens. They include noroviruses (Norwalk virus [NV]
and MD145 virus) and feline calicivirus (FCV), in the Caliciviridae
family; human rhinovirus (HRV), enterovirus 71 (EV71), polio-
virus (PV), foot-and-mouth disease virus (FMDV), hepatitis A
virus (HAV), and porcine teschovirus (PTV), in the Picornaviri-
dae family; and human coronavirus 229E, transmissible gastroen-
teritis virus (TGEV), murine hepatitis virus (MHV), bovine coro-
navirus (BCV), feline infectious peritonitis virus (FIPV), and
severe acute respiratory syndrome coronavirus (SARS-CoV), in
the Coronaviridae family. Therefore, great efforts have been made
to discover effective preventive and therapeutic measures, includ-
ing vaccines and antiviral agents, against these viruses. The devel-
opment and implementation of the PV vaccine in children for the
prevention of poliomyelitis represent an example of successful
control of viral diseases. Still, there are many challenges on the way
toward the development of effective vaccines for some of these
viruses, such as diverse serotypes, short-term immunity, or an
inability to grow the virus in cell culture.
At present, no antiviral drug specific for viruses belonging to
the picornavirus-like supercluster has been approved by the FDA.
The importance of these RNA viruses as human and animal
pathogens and the lack of antiviral drugs make it imperative to
develop therapeutics against these viruses. Traditionally, antiviral
drug development has focused on virus-specific approaches due
to the widely diverse replication strategies and antigenicity of vi-
ruses and the limited knowledge of a common therapeutic target.
Exceptions are interferons, which are a part of innate immunity
that act as natural antivirals to counteract various viral pathogens.
Recently, synthetic compounds and several protease inhibitors
were shown to be effective against multiple viruses in single (6, 12,
44) or multiple (18, 25, 26, 38, 43) virus families. For example, the
protease inhibitor rupintrivir, originally developed for HRV,
and/or its derivatives also showed broad-spectrum antiviral activ-
ity against picornaviruses and coronaviruses in cell culture (6, 12,
44), underscoring the potential development of broad-spectrum
antivirals.
A common feature of the viruses in the picornavirus-like su-
percluster is that they possess a viral 3C or 3C-like protease (3Cpro
or 3CLpro, respectively) which is responsible for the majority of
cleavages of the corresponding viral polyprotein into mature or
intermediate virus proteins (4, 41). The 3Cpro and 3CLpro share
several common characteristics, including a typical chymotryp-
sin-like fold; a Cys residue as an active site nucleophile in the
catalytic triad (or dyad), composed of Cys, His, and Glu (or Asp)
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residues; and a preference for a Glu or Gln residue at the P1 posi-
tion on the substrate (in the nomenclature of Schechter and
Berger [36]). The structural conservation of the active sites con-
taining the catalytic triad or dyad and of substrate binding pockets
has been shown by high-resolution three-dimensional (3D) struc-
tures of the 3Cpro and 3CLpro of these viruses (2, 19, 29, 30, 45,
46). Since virus proteases are essential for virus replication, the
conserved key sites of 3Cpro or 3CLpro may serve as attractive
targets for the design of antiviral drugs.
We previously identified a series of protease inhibitors (28, 40),
including a dipeptidyl aldehyde (GC373) and an -ketoamide
(GC375), and evaluated their efficacy against NV in enzyme- and
cell-based assays. In this study, we synthesized a dipeptidyl bisul-
fite adduct salt (GC376) from GC373 and evaluated the activities
of GC373, GC375, and GC376 against various viruses in the picor-
navirus-like supercluster in enzyme- and/or cell-based assays. The
viruses and virus proteases tested in this study included calicivi-
ruses (NV, MD145, murine norovirus [MNV], and FCV), coro-
naviruses (229E, TGEV, MHV, BCV, FIPV, and SARS-CoV), and
picornaviruses (HAV, PV, FMDV, EV71, HRV, and PTV). All
compounds were highly effective against most picornaviruses,
caliciviruses, and coronaviruses tested, with half-maximal in-
hibitory concentrations (IC50s) in the high nanomolar or low
micromolar range in cell-based or protease assays and with
high therapeutic indices. The crystal structures of NV 3CLpro-,
PV 3Cpro-, and TGEV 3CLpro-GC376 complexes, determined at
1.65, 1.60, and 2.25 Å, respectively, revealed that GC376 cova-
lently bound to Cys 139, Cys 147, and Cys 144 of NV 3CLpro, PV
3Cpro, and TGEV 3CLpro, respectively. Based on our results,
these compounds have broad-spectrum antiviral activity against
multiple viruses in the picornavirus-like supercluster, including
important classical and emerging animal and human pathogens.
We conclude that members of these compound series may have
the potential to be developed as antiviral therapeutics targeting a
specific virus or, more importantly, as broad-spectrum antivirals
targeting multiple viruses.
MATERIALS AND METHODS
Compounds. GC373 and GC375 were synthesized as reported elsewhere
(28, 40). The aldehyde bisulfite adduct salt GC376 was synthesized as
described in the supplemental material. The structures of the dipeptide
inhibitors are shown in Fig. 1. Rupintrivir, a protease inhibitor designed
against HRV 3Cpro, was purchased from Axon Medchem (Groningen,
Netherlands) and used as a control.
Cells, viruses, and reagents. Various cell lines, including HG23
(Huh-7 cells containing an NV replicon) (8), CRFK, RAW267.4, ST, CCL-
9.1, MRC-5, FRhK-4, HeLa, and Vero cells, were maintained in Dulbec-
co’s minimal essential medium (DMEM) or MEM containing 5% fetal
bovine serum and antibiotics (chlortetracycline [25 g/ml], penicillin
[250 U/ml], and streptomycin [250 g/ml]). All cells except for HG23
cells were obtained from ATCC (Manassas, VA). Viruses used in this
study were FCV (strain Urbana), MNV-1, TGEV (strain Miller), BCV (a
field isolate from the Kansas State University [KSU] diagnostic lab), FIPV
(strain 1146), human coronavirus 229E, MHV (strain A59), HAV (strain
HM175), PTV (a field isolate from the KSU diagnostic lab), enterovirus 71
(strain H), and HRV (strains 18, 51, and 68). FCV and MNV-1 were
obtained from K. Green at the NIH and from H. Virgin at Washington
University (St. Louis, MO), respectively. BCV and PTV were obtained
from the KSU diagnostic lab. All other viruses were obtained from ATCC.
Expression and purification of 3Cpro and 3CLpro. The cDNAs en-
coding full-length viral 3Cpro or 3CLpro of TGEV and HAV were ampli-
fied by reverse transcription-PCR (RT-PCR) as previously described (2,
37). Primers contained the nucleotide sequences of each corresponding
protease, for cloning, as well as the nucleotides for 6 His residues (in the
forward primers). The codon-optimized cDNAs for 3Cpro or 3CLpro of
NV, MD145, SARS-CoV (3), PV (31), and FMDV (7) were synthesized
fused with 6 His at the N terminus (Genscript, Piscataway, NJ). Each
synthesized gene or amplified product was subcloned into the pET-
28a() vector. The expression and purification of each protease were
FIG 1 Structures (A) and summary of synthesis (B) of dipeptide inhibitors. GC373, GC375, and GC376 are shown, with aldehyde, -ketoamide, and aldehyde
bisulfite adduct salt, respectively, as warheads.
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performed by a standard method described previously by our lab (39).
Recombinant HRV 3Cpro was purchased from EMD Chemicals, Inc.
(Gibbstown, NJ).
FRET protease assays. Fluorogenic substrates with Edans and Dabcyl
as a donor and quencher pair were purchased from Bachem (coronavirus
substrate) or synthesized by GenScript. The viral proteases and the corre-
sponding fluorogenic substrates are listed in Table 1, along with their
sources. The designation of substrate residues for P1 and P1= starts at the
scissile bond and counts toward the N and C termini, respectively (36).
The fluorescence resonance energy transfer (FRET) protease assay was
performed as follows. Stock solutions (10 mM) of the substrates and the
compounds were prepared in dimethyl sulfoxide (DMSO) and diluted in
assay buffer. The assay buffer comprised 20 mM HEPES buffer containing
NaCl (0 mM for HAV 3Cpro and 200 mM for all other proteases), 0.4 mM
EDTA, glycerol (60% for NV and MD145 3CLpro and 30% for TGEV and
229E 3CLpro), and 6 mM (NV and MD145 3CLpro and HAV 3Cpro) or
4 mM (all other proteases) dithiothreitol (DTT) at pH 6 (coronavirus
3CLpro) or 8 (all other proteases) (9). Each protease was mixed with serial
dilutions of each compound or with DMSO in 25 l of assay buffer and
incubated at 37°C for 30 min, followed by the addition of 25 l of assay
buffer containing substrate. Fluorescence readings were obtained using an
excitation wavelength of 360 nm and an emission wavelength of 460 nm
on a fluorescence microplate reader (FLx800; Biotek, Winooski, VT) 1 h
following the addition of substrate. Relative fluorescence units (RFU)
were determined by subtracting background values (substrate-containing
well without protease) from the raw fluorescence values as described pre-
viously (9, 22). The dose-dependent FRET inhibition curves were fitted
with a variable slope by using GraphPad Prism software (GraphPad, La
Jolla, CA) in order to determine the IC50s of compounds.
Cell-based inhibition assays. The effects of each compound on viral
replication were examined in cell culture systems. Virus-infected cells
were incubated at 37°C, except for HRV-infected HeLa cells, which were
maintained at 33°C. The viruses and corresponding cell lines are listed in
Table 2. Briefly, confluent or semiconfluent cells were inoculated with
virus at a multiplicity of infection of 0.05 for 1 h, and the inoculum was
replaced with medium containing DMSO (0.1%) or each compound
(up to 100 M). The virus-infected cells were further incubated for up to
168 h, and the replication of virus was measured by the 50% tissue culture
infective dose (TCID50) method (35) and/or real-time quantitative RT-
PCR (qRT-PCR). The TCID50 method was used for titration of viruses
showing apparent cell cytopathic effects, which included FCV, MNV-1,
TGEV, FIPV, MHV, BCV, HAV, 229E, EV71, and PTV. Real-time qRT-
PCR was performed for titration of NV (replicon-harboring cells) and
HRV. For HAV and 229E, real-time qRT-PCR was also used to confirm
the TCID50 results. For real-time qRT-PCR, RNA was extracted from each
sample (cell lysates for HG23 cells and viral suspensions for HAV, HRV,
and 229E) by use of an RNeasy kit (Qiagen, Valencia, CA), followed by am-
plification in a Cepheid SmartCycler with the following parameters: 45°C for
30 min and 95°C for 10 min followed by 40 cycles of denaturation at 95°C for
30 s, annealing at 50°C for 1 min, and elongation at 72°C for 30 s. The primers
and probes used for real-time qRT-PCR included the following: for NV, 5=-
CGYTGGATGCGNTTYCATGA-3=, 5=-CTTAGACGCCATCATCATTY
AC-3=, and 6-carboxyfluorescein (FAM)–5=-AGATYGCGATCYCCTGT





kFQ; and for 229E, 5=-TTCCGACGTGCTCGAACTTT-3=, 5=-CCAACA
CGGTTGTGACAGTGA-3=, and FAM-5=-TCCTGAGGTCAATGCA-3=-
IABkFQ. The IC50s were determined by GraphPad Prism software.
Nonspecific cytotoxic effects. The toxic dose for 50% cell death
(TD50) for each compound was determined for the various cells used in
TABLE 1 Virus proteases and fluorogenic substrates used for FRET protease assaysa
Virus family and virus Fluorogenic substrate
Source and/or reference for
fluorogenic substrate
Buffer conditionsb
pH Glycerol (%) DTT (mM) NaCl (mM)
Caliciviridae
NV Edans-DFHLQ/GP-Dabcyl (truncated) 46 8 60 6 120
MD145 Edans-DFHLQ/GP-Dabcyl 8 60 6 120
Coronaviridae
TGEV Dabcyl-KTSAVLQ/SGFRKME-Edans Bachem; 24 6 30 4 120
SARS-CoV Dabcyl-KTSAVLQ/SGFRKME-Edans 6 30 4 120
Picornaviridae
PV Dabcyl-KTSAVLQ/SGFRKME-Edans 8 20 4 120
HRV Edans-DFHLQ/GP-Dabcyl 7 20 4 120
HAV Dabcyl-GLRTQ/SFS-Edans Bachem 7 20 4 120
FMDV Edans-APAKQ/LLN-Dabcyl 22 8 50 4 120
a NV, norovirus strain Norwalk; MD145, norovirus strain MD145; TGEV, transmissible gastroenteritis virus; SARS-CoV, severe acute respiratory syndrome coronavirus; PV,
poliomyelitis virus; HRV, human rhinovirus; HAV, human hepatitis A virus; FMDV, foot-and-mouth disease virus.
b The buffer contained 20 mM HEPES and 0.4 mM EDTA.
TABLE 2 Viruses and corresponding cell lines used in cell culture











HRV 18, 51, and 68 HeLa
PTV ST
a MNV-1, murine norovirus 1; FIPV, feline infectious peritonitis virus; 229E, human
coronavirus 229E; MHV, mouse hepatitis virus; BCV, bovine coronavirus; EV71,
enterovirus 71; HRV 18, 51, and 68, human rhinovirus strains 18, 51, and 68; PTV,
porcine teschovirus.
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this study. Confluent cells grown in 96-well plates were treated with var-
ious concentrations (1 to 500 M) of each compound for 72 h. Cell cyto-
toxicity was measured by a CytoTox 96 nonradioactive cytotoxicity assay
kit (Promega, Madison, WI) and crystal violet staining. The in vitro ther-
apeutic index was calculated by dividing the TD50 by the IC50.
X-ray crystallography: crystallization and data collection. Details
regarding crystallization, data collection, structure solution, and refine-
ment are provided in Table S1 in the supplemental material. Briefly, all
crystallization trials were conducted in high-throughput Compact Jr.
(Emerald Biosystems) sitting-drop vapor diffusion plates at 20°C, using
equal volumes of protein and crystallization solution equilibrated against
75 l of the latter. Crystals of apo-NV 3CLpro or an NV 3CLpro-, PV
3Cpro-, or TGEV 3CLpro-GC376 complex were obtained within 48 h (see
Fig. S1), and X-ray diffraction data were collected at Advanced Photon
Source beamline 17-ID, using a Dectris Pilatus 6 M pixel array detector.
Structure solution was conducted by molecular replacement with Molrep
(42), and refinement and model building were carried out with Phenix (1)
and Coot (15), respectively.
Protein structure accession numbers. Coordinates and structure fac-
tors for apo-NV 3CLpro and the NV 3CLpro-, PV 3Cpro-, and TGEV
3CLpro-GC376 complexes have been deposited in the Protein Data Bank
(PDB) under accession numbers 3UR6, 3UR9, 4DCD, and 4F49, respec-
tively.
RESULTS
Effects of compounds against 3Cpro or 3CLpro of viruses in the
picornavirus-like supercluster. Viral 3Cpro or 3CLpro, except
for HRV 3Cpro, which was purchased from a commercial source,
were expressed and optimized for protease assays with the fluoro-
genic substrates presented in Table 1. The effects of the com-
pounds as well as rupintrivir in optimized FRET protease assays
are summarized in Table 3. GC373 (dipeptidyl aldehyde) (Fig. 1),
previously shown to be effective against NV 3CLpro (40), inhib-
ited the activities of all viral proteases except for HAV 3Cpro; it
was effective against the proteases of caliciviruses (NV and MD145
virus), coronaviruses (TGEV and SARS-CoV), and picornaviruses
(PV, FMDV, and HRV), with IC50s ranging from 0.61 to 3.48 M
under our assay conditions (Table 3). The effects and range of
inhibition of GC376 were comparable to those of GC373 against
various 3Cpro and 3CLpro. The inhibitory effects of GC375 (a
dipeptidyl -ketoamide) were moderate (2.87 to 4.02 M) against
the proteases of caliciviruses (Table 3). However, the inhibitory
activities of GC375 against the proteases of picornaviruses and
coronaviruses were comparable to those of GC373 and GC376
(Table 3). In addition, GC375 showed weak but appreciable in-
hibitory effects on HAV 3Cpro compared to GC373 and GC376.
Rupintrivir, used as a control, showed similar activities against
calicivirus and picornavirus proteases compared to GC373 and
GC376 but was substantially less effective against the coronavirus
proteases (Table 3).
Effects of compounds on the replication of viruses in the pi-
cornavirus-like supercluster. The overall effects of the com-
pounds on the replication of various viruses in the cell-based as-
says were in line with those in the protease assay (Tables 3, 4, and
5). Both GC373 and GC376 were significantly effective against
caliciviruses (NV and MNV-1), coronaviruses (TGEV, FIPV,
MHV, 229E, and BCV), and picornaviruses (HRVs 18, 51, and 68,
EV71, and PTV), with nanomolar or low micromolar IC50s, ex-
cept for FCV and HAV (Tables 4 and 5). Interestingly, FCV was
less sensitive to GC373 and GC376, with IC50s of 65 and 35 M,
respectively (Table 4). As shown with the protease assay, GC373
and GC376 showed no or weak effectiveness against the replica-
tion of HAV in cells. GC375 showed significant antiviral effects
against NV and all coronaviruses and picornaviruses, including
HAV, but no effects against FCV and MNV-1 at concentrations up
to 50 M (Tables 4 and 5). Rupintrivir inhibited the replication of
NV (in HG23 cells), TGEV, FIPV, 229E, BCV, HRV strains 18, 51,
and 68, EV71, and PTV, with various potencies (Tables 4 and 5).
Note that rupintrivir did not inhibit the replication of MNV-1,
FCV, and MHV at concentrations up to 50 M or 100 M (Tables
4 and 5). All compounds, including rupintrivir, did not show any
nonspecific cytotoxicity at concentrations up to 500 M in the
cells used for virus replication in this study.
TABLE 3 Effects of GC373, GC375, and GC376 on 3Cpro or 3CLpro of viruses in the FRET protease assay
Drug
Inhibition (IC50 [M]) of recombinant 3Cpro or 3CLpro
a
Caliciviruses Coronaviruses Picornaviruses
NV MD145 TGEV SARS-CoV HAV HRV PV FMDV
GC373 0.64  0.27 1.18  0.52 0.99  0.12 3.48  1.59 50 0.65  0.36 2.02  1.56 0.61  0.32
GC375 2.87  0.39 4.02  2.19 1.55  0.10 4.66  0.19 42.59  2.61 0.55  0.39 2.84  0.25 0.55  0.32
GC376 0.49  0.05 0.96  0.65 0.82  0.47 4.35  0.47 50 0.20  0.14 1.77  0.31 1.16  0.75
Rupintrivir 0.83  0.19 0.70  0.19 50 50 50 0.34  0.05 1.83  0.38 4.21  1.97
a The IC50s are means  standard errors of the means for two or three independent tests with each optimized protease assay.
TABLE 4 Effects of GC373, GC375, and GC376 on replication of viruses in cell culture as determined by the TCID50 method
Drug
Inhibition (IC50 [M]) of virus (mean  SEM)
a
Caliciviruses Coronaviruses Picornaviruses
FCV MNV-1 TGEV FIPV MHV 229E BCV HAV EV71 PTV
GC373 65.1  2.1 6.5  1.2 0.3  0.2 0.3  0.1 2  0.2 0.2  0.1 0.7  0.2 100 11.1  1.2 0.15  0.1
GC375 50 50 0.2  0.1 1.5  0.3 4.5  0.4 0.25  0.1 0.8  0.2 19.5  2.1 15.2  1.3 0.2  0.1
GC376 35.2  3.6 5.3  1.6 0.15  0.1 0.2  0.1 1.1  0.3 0.15  0.1 0.6  0.2 50.2  5.6 10.3  2.4 0.15  0.1
Rupintrivir 50 50 2.5  0.7 10.3  1.3 100 0.3  0.1 15.3  2.5 100 0.5  0.2 0.15  0.1
a The IC50s are averages for 3 independent tests and were determined by the TCID50 method. SEM, standard error of the mean.
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Crystal structure of NV 3CLpro refined to 1.50-Å resolution.
The apo-NV 3CLpro structure, which represents a new crystal
form of NV 3CLpro (Fig. 2A), was similar to a previously reported
crystal structure of NV 3CLpro (PDB accession no. 2FYQ) (46).
Superposition of residues Ala 1 to Ala 173 of our structure with
those of structure 2FYQ by using Superpose (23) via the CCP4
(10) interface yielded root mean square deviations (RMSD) of
0.84 Å and 0.77 Å between the C atoms for chains A and B,
respectively. The largest differences were observed in certain loop
regions of the protease, including Met 101 to Arg 112, Lys 146 to
Val 152, and Thr 161 to Thr 166, and are not likely due to crystal
contacts. These loop regions are known to be flexible and involved
in the substrate recognition and interaction for the protease activ-
ity (19, 30, 46).
Crystal structure of NV 3CLpro in complex with GC376 re-
fined to 1.65-Å resolution. NV 3CLpro existed as a noncrystallo-
graphic dimer that was nearly identical to that observed for the
apo crystal form (Fig. 2B). Examination of the active site revealed
a prominent difference in electron density (Fo  Fc) of 3 in
each subunit, consistent with GC376. However, the bisulfite
group appeared to have been removed, and the compound was
converted to the aldehyde form, which created a covalent bond
with Cys 139 (Fig. 3A). The 6-membered aromatic ring of the
compound is not included in the modeling due to disorder, which
may have resulted from the possibility that the aromatic ring does
not bind to the S3 site but faces outwards toward the solvent (Fig.
3A). The glutamine surrogate ring and the Leu of GC376 fit into
the S1 and S2 sites, respectively, as expected (Fig. 3B). The hydro-
gen bond interactions between amino acid residues His 30, Gln
110, Thr 134, His 157, Ala 158, and Ala 160 in NV 3CLpro and
GC376 are shown in Fig. 3C. Superposition of residues Ala 1 to Ala
173 of apo-NV 3CLpro with those of the NV 3CLpro-GC376 com-
plex yielded RMSD of 0.80 Å and 0.68 Å between the C atoms for
chains A and B, respectively. The largest differences were observed
in the loop containing Gln 110, which undergoes a conforma-
tional change to accommodate hydrogen bonding to GC376
(Fig. 4A; see Movie S1 in the supplemental material). Gln 100 and
Ala 160 are involved in tight binding to GC376, with large confor-
mational changes in the loops containing those amino acids. All
other residues that form hydrogen bonds to the compound are in
similar positions in both the apo and ligand-bound forms. Com-
parison of the binding interactions between 3CLpro of norovirus
strain Southampton and a Michael acceptor inhibitor, acetyl-
Glu-Phe-Gln-Leu-Gln-CHACHCOO (19), and between NV
3CLpro and dipeptidyl GC376 demonstrated that the same amino
acids were involved in the interactions with the inhibitors.
Crystal structures of PV 3Cpro and TGEV 3CLpro in com-
plex with GC376, refined to 1.6-Å and 2.25-Å resolution, respec-
tively. The proteases of a picornavirus (PV 3Cpro) and a corona-
virus (TGEV 3CLpro) were selected to study the interaction with
GC376 in comparison to that with NV 3CLpro (Fig. 3D to I).
Examination of the active site revealed a prominent difference in
electron density (Fo  Fc) in each subunit (3) that was consis-
tent with GC376 (Fig. 3D and G). Like the case with NV 3CLpro,
the glutamine surrogate ring and Leu of GC376 fit into the S1 and
S2 sites, respectively (Fig. 3E and H), as expected. The GC376-
bound structures of PV 3Cpro and TGEV 3CLpro are similar
overall to the corresponding apo crystal forms (PV 3Cpro [PDB
accession no. 1L1N] and TGEV 3CLpro [PDB accession no.
2AMP]). Hydrogen bonding interactions between PV 3Cpro or
TGEV 3CLpro and GC376 are shown in Fig. 3F and I. For the PV
3Cpro-GC376 complex, the hydrogen bond interactions between
amino acid residues His 40, Leu 127, Gly 128, Thr 142, His 161,
Val 162, and Gly 164 in the protease and the compound are shown
in Fig. 3F. Superposition of residues Ala 7 to Leu 174 of apo-PV
3Cpro with those of the PV 3Cpro-GC376 complex yielded an
RMSD of 0.83 Å between the C atoms. The largest differences
that occur upon ligand binding were observed in the loops con-
taining Leu 127, Gly 128, and Thr 142 (Fig. 4B). Leu 127 and Gly
128 undergo a conformational change to accommodate a water-
mediated hydrogen bond with the compound, and Thr 142 moves
to form a hydrogen bond with the pyrrolidine ring of GC376 (Fig.
4B; see Movie S2 in the supplemental material). For the TGEV
TABLE 5 Effects of GC373, GC375, and GC376 on replication of viruses
in cell culture as determined by real-time qRT-PCR
Drug
Inhibition (IC50 [M]) of virus (mean  SEM)
a
Caliciviruses Picornaviruses
HG23 HRV18 HRV51 HRV68
GC373 0.2  0.1 1.1  0.3 1.8  0.3 1.6  0.2
GC375 2.8  0.3 0.09  0.03 0.08  0.02 0.07  0.02
GC376 0.3  0.1 1.2  0.2 1.5  0.2 0.8  0.2
Rupintrivir 2.3  0.5 0.03  0.01 0.02  0.01 0.04  0.02
a The IC50s are averages for 3 independent tests and were determined by real-time qRT-
PCR. SEM, standard error of the mean.
FIG 2 Crystal structures of apo-NV 3CLpro and NV 3CLpro in complex with GC376. (A) Noncrystallographic symmetry (NCS) dimer of NV 3CLpro showing
chain A (blue) and chain B (magenta). (B) NCS dimer of apo-NV 3CLpro showing chain A (magenta) and chain B (blue) superimposed with the GC376-bound
form showing chain A (cyan) and chain B (green).
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3CLpro-GC376 complex, the hydrogen bond interactions be-
tween amino acid residues Thr 47, Phe 139, His 162, His 163, and
Glu 165 in the protease and the compound are shown in Fig. 3I.
The interactions between PV 3Cpro and GC376 also lead to con-
formational changes in loops containing Leu 127, Gly 128, and Gly
164 to accommodate hydrogen bonding. Like NV 3CLpro, the
inhibitor was converted to the aldehyde form, which created a
covalent bond with Cys 147 or Cys 144 in PV 3Cpro or TGEV
3CLpro, respectively. Water-mediated contacts between the pro-
tein and inhibitor were observed for PV 3Cpro and TGEV
3CLpro, as shown in Fig. 3. The B factors for these water molecules
were 28.7 Å2 and 36.5 Å2 for PV 3Cpro, similar to the average B
factor for all atoms in the model (22.7 Å2). For TGEV 3CLpro, a
single water-mediated contact was observed in a similar position
in 3 of the 4 subunits. The B factors for these water molecules were
34.8 Å2, 35.3 Å2, and 30.8 Å2 (subunits A, B, and C, respectively),
comparable to the average B factors for all atoms (31.9 Å2). In
addition, the water molecules fit well to the electron density maps,
with no residual positive or negative density observed in the Fo 
Fc map following refinement.
FIG 3 Cocrystal structures of NV 3CLpro, PV 3Cpro, and TGEV 3CLpro in complex with GC376. (A to C) NV 3CLpro-GC376 complex. (A) Fo  Fc omit map
contoured at 3 for GC376. The aromatic ring of the inhibitor (green) was not included in the model due to disorder. (B) GC376 (red) in the S1 and S2 positions
of the active site of NV 3CLpro (gray). (C) Hydrogen bonding (dashed lines) interactions between NV 3CLpro (cyan) and GC376 (gray). (D to F) PV
3Cpro-GC376 complex. (D) Fo  Fc omit map contoured at 3 for GC376. (E) GC376 (red) in the S1 and S2 positions of the active site of PV 3Cpro (gray). (F)
Hydrogen bonding (dashed lines) interactions between PV 3Cpro (magenta) and GC376 (gray). (G to I) TGEV 3CLpro-GC376 complex. (G) Fo  Fc omit map
contoured at 3 for GC376. (H) GC376 (red) in the S1 and S2 positions of the active site of TGEV 3CLpro (gray). (I) Hydrogen bonding (dashed lines)
interactions between PV 3Cpro (magenta) and GC376 (blue). The red spheres in panels F and I are water molecules.
FIG 4 Conformational changes during binding of NV 3CLpro or PV 3Cpro and GC376. (A) Conformational changes in the loop containing Gln 110 in NV
3CLpro that occur upon inhibitor binding (see Movie S1 in the supplemental material for details). The apo and inhibitor-bound forms are colored magenta and
cyan, respectively. The hydrogen bonds that form between Gln 110 and the inhibitor are indicated by dashed lines. (B) Conformational changes in the loops
containing Leu 127, Gly 128, and Thr 142 of PV 3Cpro that occur upon ligand binding (see Movie S2 for details). The apo and ligand-bound forms are colored
green and magenta, respectively. Leu 127 and Gly 128 undergo a conformational change to accommodate a water-mediated hydrogen bond. The red spheres are
water molecules.
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Viral proteases have been an important target for the development
of antiviral drugs. Examples include several protease inhibitors
currently on the market or under development for the treatment
of viral infections, including infections with human immunode-
ficiency virus and hepatitis C virus (11, 27). The viruses in the
picornavirus-like supercluster are characterized by the conserved
viral genes, including those coding for 3Cpro or 3CLpro (see Fig.
S2A and B in the supplemental material). The 3Cpro and 3CLpro
possess common characteristics, such as conserved active sites
with a Cys residue as a nucleophile, which may serve as useful
targets for the design of antiviral drug development. Previously,
we reported a series of dipeptidyl transition state inhibitors of NV
3CLpro (28, 40). Since NV 3CLpro shares sequence and structural
similarities in the active site with those of picornaviruses and coro-
naviruses, we evaluated the dipeptidyl inhibitors for activity
against various viruses in the picornavirus-like supercluster in a
protease assay and/or cell-based system. In addition, we generated
an inhibitor possessing a bisulfite adduct warhead (GC376) with
the same backbone as that of previously generated dipeptidyl in-
hibitors and examined its broad-spectrum antiviral activity.
The viruses selected for evaluation in our study are important
human and animal pathogens in the Caliciviridae, Coronaviridae,
and Picornaviridae families. The Caliciviridae family includes 4
genera, namely, Vesivirus, Lagovirus, Norovirus, and Sapovirus.
The NV and MD145 strains belong to norovirus genotypes I and
II, respectively. Noroviruses of these genotypes are associated with
the majority of norovirus outbreaks in humans. Viruses in the
Coronaviridae family are divided into groups I, II, and III, and
tentatively classified group IV (SARS-CoV), based upon antigenic
properties and sequence homology. Coronaviruses in groups I
and II infect mammals. The viruses or viral proteases tested in our
study include those from groups I (229E, TGEV, and FIPV) and II
(MHV and BCV) and SARS-CoV. The coronavirus 229E is a com-
mon cause of common cold in humans. SARS-CoV causes severe
acute respiratory syndrome, with a high fatality rate, and was re-
sponsible for more than 800 fatalities in global outbreaks of SARS
in 2003 (34), which accelerated studies on the development of
effective antivirals against coronaviruses. TGEV, BCV, MHC, and
FIPV are important animal pathogens with significant economic
consequences or high fatality rates. Members of the Picornaviridae
family are among the most diverse viruses and the most common
causes of human viral infections. Picornaviruses have 12 distinct
genera, including Enterovirus (PV and HRV), Cardiovirus, Aph-
thovirus (FMDV), Hepatovirus (HAV), and Teschovirus (PTV).
These viruses exhibit a marked range of diversity in areas such as
hosts, symptoms, and viral antigenicity. For example, HRV is a
major cause of common cold in humans, with more than 100
distinct serotypes. PV is the causative agent of poliomyelitis, a
devastating disease in humans. HAV is responsible for an acute
hepatitis, affecting tens of millions of individuals each year in areas
with poor hygiene standards (21). FMDV is highly contagious in
domestic livestock, and FMDV outbreaks can result in devastating
economic losses and international trade embargoes (17). Despite
the diversity of these viruses in diseases and hosts, the advance-
ment of refined structural elucidation of their 3C or 3CL proteases
offers an opportunity for exploring inhibitors that are applicable
to diverse viruses possessing these viral proteases.
The structures of the active sites and the substrate specificity of
3Cpro or 3CLpro are well elucidated. In most 3Cpro or 3CLpro,
the P1 and P2 positions at the cleavage sites in the viral polypro-
teins are most commonly occupied by Gln (or Glu) and a hydro-
phobic residue, respectively (41). The inhibitors used in this study
are dipeptidyl compounds with a Gln surrogate structure in a
position that corresponds to the P1 position and a Leu in the P2
position (Fig. 1). Our dipeptidyl compounds of this particular
structure exhibit broad antiviral activity against diverse viruses
across multiple virus families possessing 3Cpro or 3CLpro with
key conserved sites. In our enzyme- and/or cell-based studies,
both GC376 and GC373 showed strong inhibition against viral
replication or viral protease activity of most viruses tested that
belong to the Caliciviridae, Coronaviridae, and Picornaviridae
families, with IC50s in the low micromolar or high nanomolar
range, except for HAV and FCV. The results indicate that dipep-
tidyl structures consisting of P1 and P2 may be sufficient for rec-
ognition and inhibition of the targeted proteases. It should be
noted that GC373 and GC376 exhibited no or low potency at
inhibiting the protease activity or replication of HAV or FCV. The
available crystallographic structure studies on HAV 3Cpro
showed that the side chains of amino acids that form the S2 pocket
allow a P2 residue with relatively small side chains, such as Ser,
Thr, or Ala residues, found in all confirmed P2 positions in the
HAV cleavage sites (5, 45). Sequence analysis of the cleavage sites
of FCV polyproteins seems to indicate that small residues such as
Ser or Ala are preferred in the S2 position, rather than bulkier
residues such as Leu or Ile. Thus, the space constraints in the S2
pocket in the protease of HAV or FCV may explain the lack of or
minimal activity of the compounds against HAV or FCV. The
compound GC375 was as potent as or more potent than GC373
and GC376 against the majority of coronaviruses and picornavi-
ruses tested, including HAV. It is possible that the active sites of
picornavirus 3Cpro and coronavirus 3CLpro have relatively
broader shapes than that of calicivirus 3CLpro, which may allow
easier accommodation of the bulkier ketoamide warhead. In con-
trast, GC375 was less effective than GC373 and GC376 against NV
replication, and even less effective against the replication of FCV
and MNV-1. It is possible that the ketoamide warhead is too bulky
to fit well into the active sites of FCV and MNV-1 proteases, which
may explain the lack of activity of the compound on the replica-
tion of those viruses.
Next, we established a binding model based on the X-ray crys-
tal structures of NV 3CLpro-, PV 3Cpro-, and TGEV 3CLpro-
GC376 complexes to examine the inhibition mechanism of
GC376. The binding of GC376 to NV 3CLpro resembled that of
acetyl-Glu-Phe-Gln-Leu-Gln-CHACHCOO to Southampton
norovirus 3CLpro, with irreversible covalent binding to Cys 139
(19). The cocrystal structure of the TGEV 3CLpro-GC376 com-
plex also demonstrated similar binding interactions between the
protease and the compound (Fig. 3G to I). These results confirm
the conserved key sites of 3Cpro or 3CLpro as attractive targets for
the design of broad-spectrum antivirals. The unexpected finding
from our X-ray crystal structures was that the bisulfite group of
GC376 was removed from the compound and GC376 was con-
verted to the aldehyde form, which subsequently led to reversible
covalent bond formation with Cys 139, Cys 147, or Cys 144 of NV
3CLpro, PV 3Cpro, or TGEV 3CLpro, respectively. This finding is
consistent with our results from preliminary studies related to the
facile transformation of aldehyde bisulfite (GC376) to aldehyde
(GC373) when the drug was administered to animals (rats) via
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intravenous and oral routes. These results suggest that the alde-
hyde bisulfite adduct compound GC376 behaves as a prodrug of
the aldehyde counterpart (Fig. 5). The bisulfite adduct warhead of
GC376 was synthesized from the precursor aldehyde by reaction
with sodium bisulfite and was intended to function as a transition
state mimic (20, 32). The high aqueous solubility and pH-depen-
dent equilibria between the precursor carbonyl compound and
bisulfite adduct were also envisaged to have a significant effect on
absorption, distribution, metabolism, excretion, and toxicity
(ADMET) and on pharmacokinetics (PK). Solubility, as well as
permeability and metabolic stability, affects oral bioavailability of
a drug in vivo and also contributes to accurate and reliable in vitro
assays. It is possible that a bisulfite adduct compound behaves as a
prodrug of the precursor aldehyde, and this warrants further stud-
ies on its effects on pharmacokinetics and pharmacodynamics.
The range of antiviral activities of these compounds highlights
the potential for the development of broad-spectrum antiviral
compounds for multiple viruses. In recent years, compounds ef-
fective against multiple viruses have been explored based on ad-
vanced knowledge of the common features of viral proteins or
host factors involved in the replication of viruses. Some enveloped
viruses, including influenza virus, vaccinia virus, vesicular stoma-
titis virus, and cytomegalovirus, which belong to different virus
families, utilize phosphatidylserine present in the host plasma
membrane for survival in host cells (43). Targeting the phospho-
lipid was proposed to be an effective strategy for the management
of infections by these enveloped viruses and proved effective in an
animal model of Lassa fever virus infection (43). As an irreversible
peptidomimetic viral protease inhibitor, rupintrivir was originally
developed for HRV, utilizing structure-based design of 3Cpro (13,
14). Rupintrivir and its derivatives were later found to have sig-
nificant antiviral activity against other related picornaviruses and
coronaviruses, as well as HRV, in cell culture (6, 12, 44). These
examples suggest that the identification of common targets may
lead to antiviral therapeutics effective against various important
human and animal viruses. Since rupintrivir was shown to be
effective against 3Cpro or 3CLpro, rupintrivir was used as a refer-
ence control in our studies (Tables 2 and 3). The compounds in
this study were found to be generally as potent as rupintrivir
against caliciviruses and picornaviruses and displayed greater po-
tency against coronaviruses. Rupintrivir and the compounds in
this study share a glutamine surrogate structure in a position cor-
responding to P1. However, the compounds in this study are di-
peptidyl compounds with lower molecular masses, i.e., 403
(GC373), 489 (GC375), and 508 kDa (GC376), than the 599-kDa
mass of rupintrivir, a tripeptidyl compound. Rupintrivir possesses
an ,	-unsaturated ester as a warhead that interacts with the thiol
group of the active site Cys in an irreversible way (33). In contrast,
our preliminary study suggested that the compounds in this study
may bind to the active site Cys by forming a reversible covalent
adduct (our unpublished data). The low molecular masses and
reversible binding mechanism of the compounds in this study
may translate into better potency, efficacy, and pharmacological
properties in vivo. Currently, we are examining their in vitro
ADMET profiles as well as in vivo pharmacokinetics, including
oral availability. In conclusion, this series of compounds target
3Cpro or 3CLpro and are effective against diverse viruses that
belong to the picornavirus-like supercluster in cell culture and/or
protease assays. The high efficacy and low toxicity of the com-
pounds described herein suggest that they may be suitable candi-
dates for further development as antivirals against one or more
viruses or could serve as a starting point for the development of
broad-spectrum antivirals.
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FIG 5 Inhibition of viral 3Cpro and 3CLpro by GC376. (A) Design of transition state inhibitors for viral 3CLpro or 3Cpro. (B) Suggested mechanism of the
aldehyde bisulfite adduct (GC376) as an inhibitor of viral 3CLpro or 3Cpro. It may act as a prodrug of the aldehyde inhibitor (GC373).
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